Overview

This trial is active, not recruiting.

Condition squamous cell carcinoma
Treatment scc metastasis
Sponsor University of Zurich
Collaborator Leiden University Medical Center
Start date November 2013
End date January 2019
Trial size 100 participants
Trial identifier NCT01976468, SCOPE-ITSCC metastases

Summary

The investigators hypothesize that a low number of SCC in OTR will metastasize.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective
Arm
organ transplant recipients
scc metastasis
occurrence of SCC metastasis

Primary Outcomes

Measure
SCC metastasis
time frame: two years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion criteria: - Organ-transplant recipients (OTR). - Histologically proven cutaneous invasive SCC at time of inclusion Exclusion criteria: - Lack of consent. - History of metastases of cutaneous SCC

Additional Information

Official title Metastases of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. The "SCOPE-ITSCC Metastases Study"
Principal investigator Günther Hofbauer, Prof MD
Description In a large international multicenter prospective observational study a total number of 1000 OTR (organ transplant recipients) with a histologically proven cutaneous SCC (squamous cell carcinoma) will be included in 10 centers and followed during 2 years to establish the cumulative incidence of metastases in OTR with cutaneous SCC.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by University of Zurich.